The latest price target for Calidi Biotherapeutics (AMEX:CLDI) was reported by Ladenburg Thalmann on June 27, 2024. The analyst firm set a price target for $1.00 expecting CLDI to fall to within 12 months (a possible -54.55% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Calidi Biotherapeutics (AMEX:CLDI) was provided by Ladenburg Thalmann, and Calidi Biotherapeutics initiated their buy rating.

There is no last upgrade for Calidi Biotherapeutics

There is no last downgrade for Calidi Biotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calidi Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calidi Biotherapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.

While ratings are subjective and will change, the latest Calidi Biotherapeutics (CLDI) rating was a initiated with a price target of $0.00 to $1.00. The current price Calidi Biotherapeutics (CLDI) is trading at is $2.20, which is out of the analyst’s predicted range.